Related Experiment Video
Updated: Aug 15, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Tumor immunoglobulin with antibody activity against blood coagulation factors
Abstract:
A cultured tumor cell line from the Greene lymphoma was shown in vitro to secrete immunoglobins of the IgG2 subclass (TcIg), which possessed a direct inhibiting effect on blood coagulation. TcIg prolonged the thrombin time (TT) of normal hamster plasma in vitro. Moreover, the effect of heparin which prolonged the plasma thrombin time was reinforced when TcIg was added to the test. This property was not neutralized by protamine sulfate. In the plasma kaolin clotting time test (KCT), the addition of TcIg lead to an anticoagulant effect, but weaker than in TT. The mixing pattern of normal plasma with tumor-bearing hamster plasma did not reveal the presence of circulating inhibitor in tumor plasma. It was suggested that TcIg had heparin-like activity.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Tumor Immunotherapy

